The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pipamperone. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Dextromethorphan. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Raclopride. Palonosetron may increase the serotonergic activities of Zolmitriptan. Methylergometrine may increase the vasoconstricting activities of Zolmitriptan. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Risperidone. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Rizatriptan. The serum concentration of Zolmitriptan can be increased when it is combined with Amphetamine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fencamfamine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Remoxipride. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Methadone. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Perospirone. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Escitalopram. The metabolism of Zolmitriptan can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Desvenlafaxine. The metabolism of Zolmitriptan can be decreased when combined with Azithromycin. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ergoloid mesylate. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tetrahydropalmatine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thiothixene. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Cyclobenzaprine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Reserpine. The risk or severity of adverse effects can be increased when Cabergoline is combined with Zolmitriptan. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Iloperidone. The metabolism of Zolmitriptan can be decreased when combined with Midostaurin. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lurasidone. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Mirtazapine. Tropisetron may increase the serotonergic activities of Zolmitriptan. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Moclobemide. The metabolism of Zolmitriptan can be decreased when combined with Pheniprazine. The metabolism of Zolmitriptan can be decreased when combined with Octamoxin. The metabolism of Zolmitriptan can be decreased when combined with Caffeine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Cariprazine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Paroxetine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Paliperidone. Dolasetron may increase the serotonergic activities of Zolmitriptan. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Linezolid. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Imipramine. The metabolism of Zolmitriptan can be decreased when combined with Iproniazid. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thioridazine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Procarbazine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluoxetine. The risk or severity of adverse effects can be increased when Tramadol is combined with Zolmitriptan. The risk or severity of adverse effects can be increased when Eletriptan is combined with Zolmitriptan. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Chlorpromazine. The serum concentration of Zolmitriptan can be increased when it is combined with Propranolol. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Perazine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Molindone. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sertindole. The serum concentration of Zolmitriptan can be increased when it is combined with Peginterferon alfa-2b. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amitriptyline. The metabolism of Zolmitriptan can be decreased when combined with Furazolidone. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pethidine. The risk or severity of adverse effects can be increased when Trazodone is combined with Zolmitriptan. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Metoclopramide. The metabolism of Zolmitriptan can be decreased when combined with Safrazine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Nefazodone. The metabolism of Zolmitriptan can be decreased when combined with Phenoxypropazine. The metabolism of Zolmitriptan can be decreased when combined with Benmoxin. The metabolism of Zolmitriptan can be decreased when combined with Bortezomib. The metabolism of Zolmitriptan can be decreased when combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Asenapine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Haloperidol. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amisulpride. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Dapiprazole. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Acetophenazine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Duloxetine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sumatriptan. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Triflupromazine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Promethazine. The serum concentration of Zolmitriptan can be decreased when it is combined with Cyproterone acetate. The metabolism of Zolmitriptan can be decreased when combined with Nialamide. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Quetiapine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Bifeprunox. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Bromperidol. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Benperidol. The metabolism of Zolmitriptan can be decreased when combined with Nevirapine. The metabolism of Zolmitriptan can be decreased when combined with Pargyline. The metabolism of Zolmitriptan can be decreased when combined with Lobeglitazone. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Maprotiline. The serum concentration of Zolmitriptan can be increased when it is combined with Vemurafenib. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Prothipendyl. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Aceprometazine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Rasagiline. The metabolism of Zolmitriptan can be decreased when combined with Iproclozide. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sertraline. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Naratriptan. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Loxapine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ziprasidone. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Osanetant. The metabolism of Zolmitriptan can be decreased when combined with Trans-2-Phenylcyclopropylamine. The serum concentration of Zolmitriptan can be increased when it is combined with Abiraterone. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Trimipramine. The metabolism of Zolmitriptan can be decreased when combined with Mebanazine. The serum concentration of Zolmitriptan can be increased when it is combined with Deferasirox. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Doxepin. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Zuclopenthixol. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Propericiazine. The serum concentration of Zolmitriptan can be increased when it is combined with Harmaline. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lorcaserin. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Mesoridazine. The metabolism of Zolmitriptan can be decreased when combined with Pirlindole. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tapentadol. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluphenazine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Desipramine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Olanzapine. The metabolism of Zolmitriptan can be decreased when combined with Tenofovir disoproxil. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Isocarboxazid. The metabolism of Zolmitriptan can be decreased when combined with Toloxatone. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amoxapine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thioproperazine. The metabolism of Zolmitriptan can be decreased when combined with Simeprevir. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amperozide. Zolmitriptan may increase the hypertensive activities of Droxidopa. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Almotriptan. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Melperone. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pipotiazine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Clomipramine. The metabolism of Zolmitriptan can be decreased when combined with Minaprine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tranylcypromine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Milnacipran. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Selegiline. The metabolism of Zolmitriptan can be decreased when combined with Rucaparib. The risk or severity of adverse effects can be increased when Vilazodone is combined with Zolmitriptan. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Perphenazine. Ondansetron may increase the serotonergic activities of Zolmitriptan. The metabolism of Zolmitriptan can be decreased when combined with Methylene blue. Tedizolid Phosphate may increase the serotonergic activities of Zolmitriptan. The serum concentration of Zolmitriptan can be increased when it is combined with Brofaromine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Ergotamine. The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Fluspirilene.